Cite
HARVARD Citation
Mateo, J. et al. (2020). Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet oncology. 21 (1), pp. 162-174. [Online].